This hasn't been a tremendous year for biotech stocks across the board, but you wouldn't know it looking at the performance these drugmakers put up in the first half of 2018. All four tripled their shareholders' money in just six short months.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,